Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

Performed for the first time ever at the nationally significant hospital "San Pio" in Benevento, led by general director ...

Pulmonx Corporation’s LUNG share price has dipped by 5.09%, which has investors questioning if this is right time to buy.

Pulmonx is known for its minimally invasive treatments for chronic obstructive pulmonary disease (COPD), including products like the Zephyr® Endobronchial Valve, which has received FDA pre-market ...

The procedure is called Endobronchial Valve Placement where it involves ... to have the procedure is to assist people with bad COPD, emphysema and who have shortness of breath.

The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon ...